Altimmune Inc
Closed
2.8 7.69
Overview
Share price change
24h
Min
2.74
Max
2.8
Income | -8.3M -27M |
|---|---|
Sales | 21K 26K |
Profit margin | -105,223.077 |
Employees | 57 |
EBITDA | -10M -29M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +295.03% upside |
Next Earnings | 12 maj 2026 |
|---|
Market Cap | 23M 544M |
|---|---|
Previous open | -4.89 |
Previous close | 2.8 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Altimmune Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Altimmune Inc Forecast
Price Target
By TipRanks
295.03% upside
12 Months Forecast
Average 11.93 USD 295.03%
High 25 USD
Low 2.5 USD
Based on 7 Wall Street analysts offering 12 month price targets forAltimmune Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
